Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Ontology highlight
ABSTRACT: The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint (IC) proteins, which act as a potent suppressor of the immune system by a myriad of mechanisms. After that, scientists focused on the immune checkpoint molecules mainly. Thereby, much effort was spent to progress novel strategies for suppressing these inhibitory axes, resulting in the evolution of immune checkpoint inhibitors (ICIs). Then, ICIs have become a promising approach and shaped a paradigm shift in tumor immunotherapies. CTLA-4 plays an influential role in attenuation of the induction of naïve and memory T cells by engagement with its responding ligands like B7-1 (CD80) and B7-2 (CD86). Besides, PD-1 is predominantly implicated in adjusting T cell function in peripheral tissues through its interact
SUBMITTER: Naimi A
PROVIDER: S-EPMC8991803 | biostudies-literature | 2022 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA